Abbott (NYSE:ABT) today unveiled a new feature within its FreeStyle Libre app for continuous glucose monitoring (CGM).
Abbott, a global healthcare leader, announced that the US Food and Drug Administration (FDA) has cleared the FreeStyle Libre 2 iOS application for use with compatible iPhones, providing a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback